Aktuellt
SENASTE
Redeye provides an initial take on Optomed’s Q4 2022 report. The year has been in line with our expectations, with total sales of EUR14.7m (EUR14.9m), which can be compared to our sales estimate of EUR14.5m. We are positive the sales were at the same level as in 2021 due to the uncertainties in China, which has clearly affected the company. We will provide an update shortly; however, as our estimates for the year were close to spot on, and our view of 2023 remains the same, we do not expect to make any major changes in our estimates for the following years and look forward to an eventful 2023.
LÄS MER
